Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Impact of age at diagnosis of de novo metastatic prostate cancer on survival.

Bernard B, Burnett C, Sweeney CJ, Rider JR, Sridhar SS.

Cancer. 2019 Nov 26. doi: 10.1002/cncr.32630. [Epub ahead of print]

PMID:
31769876
2.

The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.

Wang J, Abudurexiti M, Shao N, Wei Y, Zhu Y, Ye DW.

Eur Urol Focus. 2020 Jan 15;6(1):53-62. doi: 10.1016/j.euf.2018.08.024. Epub 2018 Sep 11.

PMID:
30217630
3.

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.

BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.

4.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.

Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.

Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.

5.

The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.

Kim KH, Han KS, Kim KH, Kim DK, Koo KC, Rha KH, Choi YD, Hong SJ.

Urol Oncol. 2015 Sep;33(9):383.e17-22. doi: 10.1016/j.urolonc.2015.04.007. Epub 2015 May 23.

PMID:
26004165
6.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.

7.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

8.

Impact of surgical margin status on prostate-cancer-specific mortality.

Chalfin HJ, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC, Humphreys E, Han M.

BJU Int. 2012 Dec;110(11):1684-9. doi: 10.1111/j.1464-410X.2012.11371.x. Epub 2012 Jul 12.

9.

Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.

Ali A, Hoyle A, Mistry H, Clarke NW.

BJU Int. 2019 Jan;123(1):65-73. doi: 10.1111/bju.14400. Epub 2018 Jun 13.

10.

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Culp SH, Schellhammer PF, Williams MB.

Eur Urol. 2014 Jun;65(6):1058-66. doi: 10.1016/j.eururo.2013.11.012. Epub 2013 Nov 20.

PMID:
24290503
11.

Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.

Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ.

Cancer. 2017 May 1;123(9):1536-1544. doi: 10.1002/cncr.30503. Epub 2017 Jan 5.

12.

The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.

Matthes KL, Pestoni G, Korol D, Van Hemelrijck M, Rohrmann S.

Urol Oncol. 2018 Jun;36(6):309.e15-309.e23. doi: 10.1016/j.urolonc.2018.02.016. Epub 2018 Mar 22.

PMID:
29576269
13.

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC.

PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.

14.

Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.

Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F, Karakiewicz PI.

Int Urol Nephrol. 2018 Jan;50(1):71-78. doi: 10.1007/s11255-017-1744-2. Epub 2017 Nov 11.

PMID:
29129028
15.

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.

Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz P.

Eur Urol Oncol. 2018 Sep;1(4):314-320. doi: 10.1016/j.euo.2018.04.013. Epub 2018 May 15.

PMID:
31100253
17.

Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.

Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ.

J Clin Oncol. 2016 Aug 20;34(24):2835-42. doi: 10.1200/JCO.2016.67.4788. Epub 2016 Jun 20.

PMID:
27325855
18.

Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis.

Muralidhar V, Mahal BA, Nguyen PL.

Radiat Oncol. 2015 Jul 30;10:155. doi: 10.1186/s13014-015-0470-0.

19.

Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2015 Nov;68(5):805-11. doi: 10.1016/j.eururo.2015.03.021. Epub 2015 Mar 21.

20.

Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.

Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, Brasso K, Vainer B, Iversen P.

Cancer. 2018 Jul 15;124(14):2931-2938. doi: 10.1002/cncr.31384. Epub 2018 May 3.

Supplemental Content

Support Center